Journal: Lung cancer (Amsterdam, Netherlands)
Article Title: Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
doi: 10.1016/j.lungcan.2023.107219
Figure Lengend Snippet: Fig. 3. Combination therapy of αPD-1 Ab plus nintedanib inhibited not only angiogenesis but also protumor TAMs. A, Representative IHC images for CD31 of sections obtained from each treatment groups. B, MVD was determined based on the ratio of the CD31-positive area to the total observation area excluding necrotic region. C, Representative IHC images for AIF-1 of sections obtained from each treatment groups. D, AIF-1-positive cell ratio was determined by dividing the number of AIF-1-positive cells by the total number of cells in randomly selected fields without necrotic areas. E, Representative IHC images for CD206 of sections obtained from each treatment groups. F, CD206-positive cell ratio was calculated by dividing the number of CD206-positive cells by the total number of cells in randomly selected fields without necrotic areas. Dot plot shows staining positive cell ratio in individual allografts from each treatment group (n = 5 each). Scale bar, 100 μm; Bars, mean ± SD. *, P < 0.05; †, P < 0.02; ‡, P < 0.01.
Article Snippet: Rabbit monoclonal Abs against VEGFR2 (#9698), PDGFRβ (#3169), FGFR1 (#9740), CD31 (#77699), CD3 (#78588), CD8 (#98941), allograft inflammatory factor-1 (AIF-1) (#17198), CD206 (#24595), Smad2/3 (#8685), nuclear factor-kappa B (NF-κB) (#8242), Src (#2109), Lyn (#2736), Lck (#2752) and GAPDH (#2118) were purchased from Cell Signaling Technology (CST, Danvers, MA).
Techniques: Staining